BRASTER S.A., the producer of the globally unique device for breast self-examination, plans to mobilise PLN 10.5 million under a public bond offering addressed mainly to individual investors. The mobilised funds are to be allocated for the support of the Company’s working capital and for the pilot project on the first foreign market. The subscriptions started on November 16. The securities are offered by IPOPEMA Securities. It is also possible to subscribe via the agents of the investment firm Expander Advisors and Grupa Finanset.

"So far, we have successfully and timely implemented all the goals of our strategy. Braster was placed on the Polish market on October 19. This way we fulfilled all our commitments made to our investors," stated Marcin Halicki, President of the Management Board of BRASTER S.A. "At the same time, we are facing new challenges. The planned foreign expansion and further development of sales in Poland are determining our working capital needs," he adds.

The funds from the bond issue will be allocated for the Company’s working capital and the pilot placement of Braster on one of the European markets in the first half of 2017.

"We hope that the offering will attract mostly individual investors. I believe that compared to, for example, bank deposits our bonds are an interesting investment option, considering the interest rate of ca. 7.5% annually," explains Marcin Halicki.

The subscriptions will be open from November 16 to 28, 2016. BRASTER offers 2.5-year bonds repurchased on request of the issuer, with fixed interest rate in the first interest period at 7.5% annually. In the subsequent interest periods, the bonds will bear a variable interest rate based on 6-month WIBOR plus an attractive interest margin of 5.7%. The interest will be payable every 6 months, with the first interest period lasting 7 months and ending at end-June 2017, and the last one being correspondingly shorter and lasting 5 months. The machinery and equipment owned by the Company will serve as a pledge for the bonds issued.

According to the 2015–2021 development strategy, the business model of BRASTER envisages ca. 70% of the Company’s revenues to originate ultimately from sales of high margin telemedical services offered in packages with the device. Following introduction of the device in Poland, which took place in October this year, the Company plans to place the device on the selected EU markets in the first half of 2017 and to enter the US market, where the sales potential is the most significant, in the second half 2017.

Subscription for bonds is possible:

directly in the Offerer’s headquarters, i.e. IPOPEMA Securities brokerage house, through the online transaction system or by phone 22 236 94 00

in chosen Agent offices of IPOPEMA Securities investment company:

Expander Advisors - 22 526 64 64

Grupa Finanset - 22 379 79 26

All details on issue parameters are presented in the Information Memorandum and in the Terms and Conditions of the Bond Issue, available at: http://www.ipopemasecurities.pl/.

See also

BRASTER started sale of its revolutionary device in Poland

Read More
BRASTER started sale of its revolutionary device in Poland

Braster - the most innovative product of Medical International Trades WIHE 2016

Read More
Braster - the most innovative product of Medical International Trades WIHE 2016
1 day 5 days 1 month Period from: to: Volume Share price pl

Raty PayU to możliwość zapłacenia za zakupy w ratach (od 3 do nawet 36)

We use cookies to improve the quality of our service. Using our website without changing the cookie settings in your browser means that you agree to have them saved or used. You can find more information in the Privacy and Cookie Policy